The API facilities are expected to be completed by 2012-13, reports business-standard.
Through its partners in China, the company is also involved in developing bio- similars/ bio-therapeutic products and the clinical trials on these drugs are expected to be completed in 2-3 years and will be launched in India.
The company said its venture into stem cell-based products is under progress with a major investment in Stempeutics Research, with a launch expected in three years.
In Europe, Cipla is expanding its presence in the inhaler segment with regulatory approvals for a few products already in place and few more in the pipeline, while in the US, the company is exploring all options including filing its own abbreviated new drug applications (ANDAs).